Bioavailability and Effectiveness of Transdermally Administered Morphine

Alberta Health services6 enrolled

Overview

Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cancer Pain

Interventions

morphineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic cancer pain * Minimum baseline pain of 3/10 * No change in medications over 3 days prior to study period * Ability to give informed consent * Willingness to undergo repeated blood sampling Exclusion Criteria: * Use of morphine or codeine in 3 days prior to study * Known sensitivity to morphine * Prior anaphylactic reaction to any opioid * Clinically significant anemia

Locations (1)

Tom Baker Cancer Centre

Calgary, Alberta, Canada

Outcomes

Primary Outcomes

detectable morphine levels in serum

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.